Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2004;110:1320-1325
Published online before print August 23, 2004, doi: 10.1161/01.CIR.0000140985.89766.CB
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
110/10/1320    most recent
01.CIR.0000140985.89766.CBv1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by von der Weid, P.-Y.
Right arrow Articles by Wallace, J. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by von der Weid, P.-Y.
Right arrow Articles by Wallace, J. L.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*ACETYLSALICYLIC ACID
*CELECOXIB
*HYDROXYUREA
*NITRIC OXIDE
Related Collections
Right arrow Other Vascular biology

(Circulation. 2004;110:1320-1325.)
© 2004 American Heart Association, Inc.


Original Articles

Aspirin-Triggered, Cyclooxygenase-2–Dependent Lipoxin Synthesis Modulates Vascular Tone

Pierre-Yves von der Weid, PhD; Morley D. Hollenberg, MD, PhD; Stefano Fiorucci, MD; John L. Wallace, PhD

From the Mucosal Inflammation Research Group (P.-Y.v.d.W., M.D.H., J.L.W.), University of Calgary, Calgary, Alberta, Canada, and the Department of Gastroenterology and Hepatology (S.F.), University of Perugia, Perugia, Italy.

Correspondence to Dr John L. Wallace, Department of Pharmacology and Therapeutics, University of Calgary, 3330 Hospital Dr NW, Calgary, Alberta, T2N 4N1 Canada. E-mail wallacej{at}ucalgary.ca

Received March 31, 2004; revision received May 17, 2004; accepted May 19, 2004.

Background— Aspirin-triggered production of 15-(R)-epilipoxin A4 (ATL) has been shown to exert potent antiinflammatory effects and gastric-protective effects, but little is known of its actions on the vasculature. In the present study, we have assessed the contribution of ATL to changes in vascular tone induced by aspirin and have examined the role of nitric oxide (NO) as a mediator of such effects.

Methods and Results— Intravenous administration of lipoxin A4 resulted in a short-lived (3 to 4 minutes) reduction in blood pressure (BP; {approx}13 mm Hg at 2.5 µg/kg). Aspirin administered alone resulted in a significant increase in serum ATL and an increase in BP of {approx}10 mm Hg. When ATL synthesis was inhibited by pretreatment with a selective cyclooxygenase-2 inhibitor (celecoxib) or a 5-lipoxygenase inhibitor (zileuton), the aspirin-induced increase in BP was significantly augmented. These agents alone did not affect BP. A lipoxin receptor antagonist, Boc2, also increased the pressor effects of aspirin. Moreover, immunodepletion of neutrophils, a major source of 5-lipoxygenase, resulted in a significant reduction of ATL formation and augmented aspirin’s pressor effects. Studies of rat aortic and mesenteric artery ring segments confirmed the vasorelaxant effects of lipoxin A4 and showed them to be endothelium dependent.

Conclusions— Aspirin-triggered lipoxin synthesis can modulate vascular tone, possibly contributing to changes in regional blood flow during inflammatory reactions, and to the modulation of systemic BP.


Key Words: inflammation • muscle, smooth • nitric oxide • vasodilation • endothelium




This article has been cited by other articles:


Home page
Pharmacol. Rev.Home page
R. D. Ye, F. Boulay, J. M. Wang, C. Dahlgren, C. Gerard, M. Parmentier, C. N. Serhan, and P. M. Murphy
International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the Formyl Peptide Receptor (FPR) Family
Pharmacol. Rev., June 1, 2009; 61(2): 119 - 161.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
B. D. Levy
Myocardial 15-Epi-lipoxin A4 Generation Provides a New Mechanism for the Immunomodulatory Effects of Statins and Thiazolidinediones
Circulation, August 29, 2006; 114(9): 873 - 875.
[Full Text] [PDF]


Home page
CirculationHome page
Y. Birnbaum, Y. Ye, Y. Lin, S. Y. Freeberg, S. P. Nishi, J. D. Martinez, M.-H. Huang, B. F. Uretsky, and J. R. Perez-Polo
Augmentation of Myocardial Production of 15-Epi-Lipoxin-A4 by Pioglitazone and Atorvastatin in the Rat
Circulation, August 29, 2006; 114(9): 929 - 935.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
B. A. Babbin, W. Y. Lee, C. A. Parkos, L. M. Winfree, A. Akyildiz, M. Perretti, and A. Nusrat
Annexin I Regulates SKCO-15 Cell Invasion by Signaling through Formyl Peptide Receptors
J. Biol. Chem., July 14, 2006; 281(28): 19588 - 19599.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
F. Cipollone, M. L. Fazia, A. Iezzi, C. Cuccurullo, D. De Cesare, S. Ucchino, F. Spigonardo, A. Marchetti, F. Buttitta, L. Paloscia, et al.
Association Between Prostaglandin E Receptor Subtype EP4 Overexpression and Unstable Phenotype in Atherosclerotic Plaques in Human
Arterioscler Thromb Vasc Biol, September 1, 2005; 25(9): 1925 - 1931.
[Abstract] [Full Text] [PDF]